Search for resonances decaying into photon pairs in 139 fb−1 of pp collisions at √s = 13 TeV with the ATLAS detector

Searches for new resonances in the diphoton final state, with spin 0 as predicted by theories with an extended Higgs sector and with spin 2 using a warped extra-dimension benchmark model, are presented using 139 fb−1 of √s = 13 TeV pp collision data collected by the ATLAS experiment at the LHC. No significant deviation from the Standard Model is observed and upper limits are placed on the production cross-section times branching ratio to two photons as a function of the resonance mass

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Search for phenomena beyond the Standard Model in events with large b-jet multiplicity using the ATLAS detector at the LHC

A search is presented for new phenomena in events characterised by high jet multiplicity, no leptons (electrons or muons), and four or more jets originating from the fragmentation of b-quarks (b-jets). The search uses 139 fb−1 of √s = 13 TeV proton–proton collision data collected by the ATLAS experiment at the Large Hadron Collider during Run 2. The dominant Standard Model background originates from multijet production and is estimated using a datadriven technique based on an extrapolation from events with low b-jet multiplicity to the high b-jet multiplicities used in the search. No significant excess over the Standard Model expectation is observed and 95% confidence-level limits that constrain simplified models of R-parity-violating supersymmetry are determined. The exclusion limits reach 950 GeV in top-squark mass in the models considered

Modelling penetration events in tissue simulants

Tissue simulants are used widely in ballistics to approximate the effect of a projectile on the human body. Many materials classically chosen to investigate such interactions are selected either for their visual effect or on an apparent structural similarity with human tissue – classic examples are soap and gelatin respectively. In this paper, the authors begin to assess the high strain-rate, dynamic mechanical response of these flesh simulants with the aim of providing material properties and calibration data to inform future hydrocode models to aid in investigation of real wounding mechanisms. To this end, equations of state (EOS) for ballistic gelatin and soap have been measured and are presented here along with physical testing data; these results provide a case for the development of hydrocode models that could ultimately predict the outcome of simulant penetrations. CT scanning has provided a useful method of extracting the physical data required for ultimate model validation

On the response of ballistic soap to one-dimensional shock loading

The effects of projectile penetration into soft tissue are often studied using the tissue simulant ballistic soap. Consequently, a full understanding of the high strain-rate response of ballistic soap is desirable. Using the plate-impact technique, key shock parameters have been measured for impacts in the range 81-968 m/s, allowing derivation of the Hugoniot equation-of-state for soap in the US-uP and P-uP planes. A linear Hugoniot relationship was found in the US-uP plane, with the general form US = 2.05 + 1.75uP (?0 = 1.107 g/cc). In P-uP space an apparent strengthening phenomenon was observed, with the Hugoniot trending above the hydrodynamic response at impact stresses greater than 1.2 GPa. Embedded lateral manganin stress gauges were employed to interrogate the evolution of lateral stress within the soap. A gradient in lateral stress, whose magnitude increased incrementally with impact stress, was apparent behind the shock for ?x > 1 GPa. This appeared to suggest a continuation of the previously highlighted strengthening mechanism. It is proposed that at higher values of ?x, increased compression of hydrocarbon chains acts to increase the material's resistance to shear, a phenomenon consistent with steric hindrance

The dynamic behaviour of ballistic soap

Ballistic soap is used as a simulant to observe the effect of a projectile penetrating soft tissue; consequently information on its behaviour at high strain-rates is desirable. The Hugoniot equation-of-state for soap has been determined using the plate-impact technique at impact velocities of 81-967 m/s. The US-uP Hugoniot was linear, taking the form US = 1.99 + 2.04uP (?0 = 1.107 g/cc). In P-uP space the Hugoniot was observed to trend substantially above the predicted hydrodynamic response for Hugoniot stresses greater than 1.2 GPa, indicative of material strengthening. The lateral-stress response of soap was interrogated using embedded lateral manganin stress gauges. Gradients observed behind the shock for ?x > 1 GPa appeared to suggest continuation of the previously observed strengthening mechanism. It is proposed at higher values of ?x, increased compression of hydrocarbon chains acts to increase the materials resistance to shear, a phenomenon known as steric hindrance